[go: up one dir, main page]

LUC00053I2 - Anticorps diriges contre cd38 pour le traitement du myelome multiple - Google Patents

Anticorps diriges contre cd38 pour le traitement du myelome multiple Download PDF

Info

Publication number
LUC00053I2
LUC00053I2 LUC00053C LUC00053I2 LU C00053 I2 LUC00053 I2 LU C00053I2 LU C00053 C LUC00053 C LU C00053C LU C00053 I2 LUC00053 I2 LU C00053I2
Authority
LU
Luxembourg
Prior art keywords
treatment
antibodies against
multiple myeloma
human
antibodies
Prior art date
Application number
Other languages
English (en)
Inventor
Weers Michel De
Graus Yvo
Oprins Judith
Parren Paul Parren
Winkel Jan Van De
Martine Van Vugt
Original Assignee
Genmab As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36617365&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LUC00053(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genmab As filed Critical Genmab As
Publication of LUC00053I1 publication Critical patent/LUC00053I1/fr
Publication of LUC00053I2 publication Critical patent/LUC00053I2/fr
Publication of LUC00053I9 publication Critical patent/LUC00053I9/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C12Y204/99002—Monosialoganglioside sialyltransferase (2.4.99.2)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/91091—Glycosyltransferases (2.4)
    • G01N2333/91148—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Reproductive Health (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
LU00053C 2005-03-23 2017-12-04 Anticorps diriges contre cd38 pour le traitement du myelome multiple LUC00053I9 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200500429 2005-03-23
US66757905P 2005-04-01 2005-04-01
US69616305P 2005-07-01 2005-07-01
US72856105P 2005-10-20 2005-10-20
EP06722861.9A EP1866338B1 (fr) 2005-03-23 2006-03-23 Anticorps diriges contre cd38 pour le traitement du myelome multiple

Publications (3)

Publication Number Publication Date
LUC00053I1 LUC00053I1 (fr) 2017-12-07
LUC00053I2 true LUC00053I2 (fr) 2018-02-21
LUC00053I9 LUC00053I9 (fr) 2018-07-03

Family

ID=36617365

Family Applications (1)

Application Number Title Priority Date Filing Date
LU00053C LUC00053I9 (fr) 2005-03-23 2017-12-04 Anticorps diriges contre cd38 pour le traitement du myelome multiple

Country Status (27)

Country Link
US (5) US7829673B2 (fr)
EP (6) EP1866338B1 (fr)
JP (12) JP5225069B2 (fr)
KR (1) KR101433381B1 (fr)
CN (4) CN119119271A (fr)
AU (1) AU2006226733C9 (fr)
BR (1) BRPI0608927B1 (fr)
CA (1) CA2602375C (fr)
CY (3) CY1118369T1 (fr)
DK (1) DK2567976T3 (fr)
EA (2) EA037929B1 (fr)
ES (1) ES2716874T3 (fr)
FR (1) FR18C1003I2 (fr)
HR (2) HRP20161766T1 (fr)
IL (8) IL322052A (fr)
LT (1) LTC2567976I2 (fr)
LU (1) LUC00053I9 (fr)
ME (1) ME03528B (fr)
MX (1) MX2007011064A (fr)
NL (1) NL300915I2 (fr)
NZ (2) NZ586780A (fr)
PL (1) PL2567976T3 (fr)
RS (1) RS59399B1 (fr)
SG (1) SG10201912554TA (fr)
SI (1) SI2567976T1 (fr)
WO (1) WO2006099875A1 (fr)
ZA (1) ZA200709003B (fr)

Families Citing this family (251)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ534399A (en) 2002-01-25 2008-08-29 G2 Therapies Ltd Monoclonal antibodies against extracellular loops of C5aR
US9200061B2 (en) 2004-02-06 2015-12-01 Morpho Sys AG Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i
MXPA06008700A (es) 2004-02-06 2007-01-19 Morphosys Ag Anticuerpos anti-cd38 humanos y usos para los mismos.
EA037929B1 (ru) * 2005-03-23 2021-06-08 Генмаб А/С Антитела к cd38 человека и их применение
HUE035250T2 (hu) 2005-10-12 2018-05-02 Morphosys Ag Humán CD38-ra specifikus teljesen humán HuCAL GOLD-eredetû terápiás ellenanyagok létrehozása és profilozása
WO2007066109A1 (fr) * 2005-12-06 2007-06-14 Domantis Limited Ligands bispecifiques ayant une specificite de liaison a des cibles de surface cellulaire et procedes d'utilisation de ceux-ci
US20130004480A1 (en) 2006-07-04 2013-01-03 Paul Parren CD20 Binding Molecules for the Treatment of Copd
US20090029904A1 (en) * 2006-07-21 2009-01-29 Sean Oldham Compositions and methods for treatment of insulin-resistance diseases
WO2008033571A2 (fr) * 2006-09-15 2008-03-20 Memorial Sloan Kettering Cancer Center Procédés de diagnostic, de traitement, ou de prévention de troubles liés aux cellules plasmatiques
ME03503B (fr) * 2006-09-26 2020-04-20 Genmab As Traitement combiné de tumeurs exprimant la cd38
WO2008040348A2 (fr) * 2006-10-03 2008-04-10 Genmab A/S Procédés haut débit de caractérisation d'anticorps
AU2013209322A1 (en) * 2006-10-19 2013-08-15 Sanofi-Aventis Novel anti-cd38 antibodies for the treatment of cancer
EP1914242A1 (fr) 2006-10-19 2008-04-23 Sanofi-Aventis Nouveau anticorps Anti-CD38 pour le traitement du cancer
US8143014B2 (en) * 2007-10-02 2012-03-27 Mayo Foundation For Medical Education And Research CD38 and obesity
EP2238169A1 (fr) 2007-12-26 2010-10-13 Biotest AG Procédé permettant de réduire les effets secondaires cytotoxiques et d'améliorer l'efficacité des immunoconjugués
CN101952315B (zh) 2007-12-26 2015-04-01 生物测试股份公司 靶向cd138的试剂及其应用
KR101579218B1 (ko) 2007-12-26 2015-12-21 바이오테스트 아게 Ｃｄ138 발현성 종양 세포에 대한 표적화를 개선시키기 위한 방법 및 물질
HRP20150143T1 (hr) * 2007-12-26 2015-04-10 Biotest Ag Imunokonjugati koji ciljaju na cd138 i njihova upotreba
ES2562627T3 (es) 2008-02-20 2016-03-07 Novo Nordisk A/S Anticuerpos anti-C5aR humanizados
GB0808350D0 (en) * 2008-05-09 2008-06-18 Airbus Uk Ltd Self-cleaning surfaces
US20110076723A1 (en) * 2008-05-23 2011-03-31 Samsung Electronics Co., Ltd. Antibody-peptide fused synergibody
US8188235B2 (en) 2008-06-18 2012-05-29 Pfizer Inc. Antibodies to IL-6 and their uses
EP2191840A1 (fr) * 2008-11-28 2010-06-02 Sanofi-Aventis Combinaisons antitumorales contenant des anticorps reconnaissant spécifiquement les CD38 et melphalan
EP2191842A1 (fr) * 2008-11-28 2010-06-02 Sanofi-Aventis Combinaisons antitumorales contenant des anticorps reconnaissant spécifiquement les CD38 et cytarabine
EP2191843A1 (fr) * 2008-11-28 2010-06-02 Sanofi-Aventis Combinaisons antitumorales contenant des anticorps reconnaissant spécifiquement les CD38 et cyclophosphamide
EP2191841A1 (fr) * 2008-11-28 2010-06-02 Sanofi-Aventis Combinaisons antitumorales contenant des anticorps reconnaissant spécifiquement les CD38 et vincristine
JP2012526079A (ja) 2009-05-06 2012-10-25 バイオテスト・アクチエンゲゼルシヤフト Ｃｄ１３８を標的とする免疫複合体の使用
AU2013201618B2 (en) * 2009-05-06 2016-06-02 Biotest Ag Uses of immunoconjugates targeting CD138
WO2011047228A1 (fr) 2009-10-16 2011-04-21 Cornell University Mesure de concentrations subcellulaires in vivo
WO2011063131A1 (fr) * 2009-11-18 2011-05-26 Nohands, Llc Procédé et système permettant de prévenir l'obésité liée à un virus et les maladies liées à l'obésité
SI2580243T1 (sl) * 2010-06-09 2020-02-28 Genmab A/S Protitelesa proti humanemu CD38
PL2621531T3 (pl) 2010-09-27 2017-07-31 Morphosys Ag Przeciwciało anty-CD38 i lenalidomid lub bortezomib do leczenia szpiczaka mnogiego i NHL
UA112170C2 (uk) * 2010-12-10 2016-08-10 Санофі Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
JOP20210044A1 (ar) * 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
JP6141834B2 (ja) * 2011-06-06 2017-06-07 ノヴォ ノルディスク アー／エス 治療抗体
US10323081B2 (en) 2011-07-06 2019-06-18 Genmag A/S Modulation of complement-dependent cytotoxicity through modifications of the C-terminus of antibody heavy chains
UA117901C2 (uk) 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
DK2771364T3 (da) 2011-10-27 2019-08-19 Genmab As Fremstilling af heterodimere proteiner
EA034989B1 (ru) 2011-10-28 2020-04-15 Тева Фармасьютикал Австралия Пти Лтд Полипептидная конструкция для применения при лечении рака, включающая аттенуированный альфа-интерферон
WO2013075740A1 (fr) 2011-11-23 2013-05-30 Sanofi Procédé de purification d'anticorps
AU2012372140B9 (en) 2011-12-08 2015-10-15 Biotest Ag Uses of immunoconjugates targeting CD138
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
US9371396B2 (en) 2012-06-15 2016-06-21 Sinomab Bioscience Limited Anti-CD22 anti-idiotypic antibodies and uses thereof
SG11201408646VA (en) 2012-07-06 2015-01-29 Genmab Bv Dimeric protein with triple mutations
EP3632462A1 (fr) 2012-07-06 2020-04-08 Genmab B.V. Protéine dimérique ayant des mutations triples
AU2013322806C1 (en) 2012-09-25 2018-03-08 Morphosys Ag Combinations and uses thereof
EP2914302B1 (fr) 2012-11-05 2017-01-04 MorphoSys AG Anticorps radiomarqué et ses utilisations
EP2914278B1 (fr) * 2012-11-05 2021-06-02 Dana-Farber Cancer Institute, Inc. Xbp1, cd138 et cs1, compositions pharmaceutiques qui comprennent les peptides et procédés d'utilisation de tels peptides et compositions
US10342869B2 (en) 2012-12-07 2019-07-09 The Regents Of The University Of California Compositions comprising anti-CD38 antibodies and lenalidomide
UA118255C2 (uk) * 2012-12-07 2018-12-26 Санофі Композиція, яка містить антитіло до cd38 і леналідомід
KR20210096697A (ko) 2013-01-10 2021-08-05 젠맵 비. 브이 인간 IgG1 Fc 영역 변이체 및 그의 용도
CN103103197A (zh) * 2013-01-30 2013-05-15 百奇生物科技（苏州）有限公司 抗cd138单克隆抗体可变区序列及其制备方法和应用
KR101990341B1 (ko) * 2013-03-12 2019-06-19 몰레큘러 템플레이츠, 인코퍼레이션. 세포 내재화를 유도하기 위한 ｃｄ20-결합 면역독소 및 이의 사용 방법
FR3003171B1 (fr) * 2013-03-15 2015-04-10 Lab Francais Du Fractionnement Nouveaux medicaments comprenant une composition d'anticorps enrichie en isoforme de charge majoritaire
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
CA2909952C (fr) 2013-04-29 2021-10-12 Teva Pharmaceuticals Australia Pty Ltd. Anticorps anti-cd38 et fusions sur un interferon alpha-2b attenue
TWI631132B (zh) 2013-05-06 2018-08-01 賽諾菲公司 用於純化抗體之連續多步驟方法
US20160235842A1 (en) * 2013-07-15 2016-08-18 The Board Of Trustees Of The Leland Stanford Junior University Medical uses of cd38 agonists
CA2927099A1 (fr) 2013-10-31 2015-05-07 Sanofi Anticorps anti-cd38 specifiques pour le traitement de cancers humains
MY176522A (en) 2013-11-04 2020-08-13 Ichnos Sciences SA Production of t cell retargeting hetero-dimeric immunoglobulins
CN105939767B (zh) 2014-01-08 2018-04-06 弗洛设计声能学公司 具有双声电泳腔的声电泳装置
JP6655017B2 (ja) 2014-01-27 2020-02-26 モレキュラー テンプレーツ, インク.Molecular Templates, Inc. Ｍｈｃクラスｉエピトープ送達ポリペプチド
JP2017506640A (ja) * 2014-02-14 2017-03-09 セントローズ， エルエルシー 細胞外標的化薬物共役体
US9732154B2 (en) * 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
EP3872090A1 (fr) * 2014-03-11 2021-09-01 Molecular Templates, Inc. Protéines comprenant des régions effectrices à sous-motifs a de shiga-toxine proches de leur extrémité amino-terminale et des régions de liaison de type immunoglobuline de ciblage cellulaire
US11142584B2 (en) 2014-03-11 2021-10-12 Molecular Templates, Inc. CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same
EP3502134B1 (fr) * 2014-03-11 2020-12-16 Molecular Templates, Inc. Protéines comportant des régions de liaison, des régions effectrices à sous-motifs a de shiga-toxine et des motifs de signal de localisation du réticulum endoplasmique carboxy-terminaux
UA119352C2 (uk) * 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
EP3137488B1 (fr) 2014-06-11 2019-01-02 Molecular Templates, Inc. Polypeptides effecteurs à sous-unités a de toxine de shiga, résistant à un clivage par protéase et molécules ciblées sur des cellules comprenant ceux-ci
WO2015195555A1 (fr) 2014-06-16 2015-12-23 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Blocage de cd38 à l'aide d'anticorps anti-cd38 conjugué à la protéine g pour protéger des cellules nk
US10106620B2 (en) 2014-06-16 2018-10-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Blocking CD38 using anti-CD38 F(ab′)2 to protect NK cells
PL3157561T3 (pl) * 2014-06-17 2020-06-29 Medimmune Limited Ulepszone przeciwciała alfa-v beta-8
WO2016011210A2 (fr) 2014-07-15 2016-01-21 Juno Therapeutics, Inc. Cellules modifiées pour thérapie cellulaire adoptive
WO2016027668A1 (fr) * 2014-08-22 2016-02-25 株式会社村田製作所 Dispositif de présentation à sensation tactile
SG11201701867SA (en) * 2014-09-09 2017-04-27 Janssen Biotech Inc Combination therapies with anti-cd38 antibodies
SG11201703251TA (en) 2014-10-29 2017-05-30 Teva Pharmaceuticals Australia Pty Ltd INTERFERON α2B VARIANTS
MA40894A (fr) * 2014-11-04 2017-09-12 Glenmark Pharmaceuticals Sa Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production
US11773166B2 (en) 2014-11-04 2023-10-03 Ichnos Sciences SA CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
WO2016089960A1 (fr) 2014-12-04 2016-06-09 Janssen Biotech, Inc. Anticorps anti-cd38 pour le traitement de la leucémie aiguë myéloïde
WO2016126950A1 (fr) 2015-02-05 2016-08-11 Molecular Templates, Inc. Molécules multivalentes de liaison à cd20 comprenant des régions effectrices de sous-unité a de la toxine shiga et compositions enrichies correspondantes
MA41555A (fr) * 2015-02-17 2017-12-26 Millennium Pharm Inc Polythérapie pour le traitement du cancer
ES2927119T3 (es) * 2015-04-08 2022-11-02 Sorrento Therapeutics Inc Productos terapéuticos de anticuerpos que se unen a CD38
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
MX380557B (es) * 2015-05-13 2025-03-12 Morphosys Ag Anticuerpos específicos para cd38 para usarse en el tratamiento de mieloma múltiple (mm).
MA42136A (fr) 2015-05-20 2018-03-28 Janssen Biotech Inc Anticorps anti-cd38 pour le traitement de l'amyloïdose à chaînes légères et d'autres tumeurs malignes hématologiques positives à cd38
UY36687A (es) 2015-05-29 2016-11-30 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Anticuerpos contra ox40 y sus usos
LT3303373T (lt) * 2015-05-30 2020-07-10 Molecular Templates, Inc. Deimunizuoto shiga toksino a subvieneto karkasai ir juos apimančios ląstelės taikinio molekulės
US10668149B2 (en) 2015-06-22 2020-06-02 Janssen Biotech, Inc. Combination therapies for heme malignancies with anti-CD38 antibodies and survivin inhibitors
EP3313441B1 (fr) * 2015-06-24 2024-02-21 Janssen Biotech, Inc. Modulation immunitaire et traitement de tumeurs solides avec des anticorps se liant spécifiquement à cd38
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
MA42895A (fr) 2015-07-15 2018-05-23 Juno Therapeutics Inc Cellules modifiées pour thérapie cellulaire adoptive
JP2018522907A (ja) 2015-08-11 2018-08-16 セレクティスＣｅｌｌｅｃｔｉｓ Ｃｄ３８抗原を標的とするためおよびｃｄ３８遺伝子を不活化するために操作された、免疫療法用の細胞
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
PH12018500950B1 (en) 2015-11-03 2023-09-20 Janssen Biotech Inc Subcutaneous formulations of anti-cd38 antibodies and their uses
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
SG10201601719RA (en) 2016-03-04 2017-10-30 Agency Science Tech & Res Anti-LAG-3 Antibodies
EP3423498A1 (fr) * 2016-03-04 2019-01-09 MorphoSys AG Évaluation clinique de réponse de protéine m dans le myélome multiple
EP3998285B1 (fr) * 2016-03-25 2025-01-22 Biomunex Pharmaceuticals Molécules de liaison pour cd38 et pd-l1
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
SG10201603721TA (en) 2016-05-10 2017-12-28 Agency Science Tech & Res Anti-CTLA-4 Antibodies
WO2018002181A1 (fr) * 2016-06-28 2018-01-04 Umc Utrecht Holding B.V. Traitement de maladies médiées par l'ige avec des anticorps qui se lient spécifiquement à cd38
SG10201911972QA (en) 2016-07-14 2020-02-27 Bristol Myers Squibb Co Antibodies against tim3 and uses thereof
JP7316930B2 (ja) * 2016-07-15 2023-07-28 武田薬品工業株式会社 形質芽細胞及び形質細胞枯渇療法に対する応答を評価するための方法及び材料
WO2018015498A1 (fr) 2016-07-20 2018-01-25 Hybrigenics Sa Combinaisons d'inéclacitol avec un agent anti-cd38 et leurs utilisations pour le traitement du cancer
KR20190070977A (ko) 2016-11-01 2019-06-21 젠맵 비. 브이 폴리펩티드 변이체 및 그의 용도
CN110167964B (zh) 2016-11-02 2023-12-01 百时美施贵宝公司 组合用于治疗多发性骨髓瘤的针对bcma和cd3的双特异性抗体和免疫药物
EP3330712A1 (fr) 2016-12-01 2018-06-06 imusyn GmbH & Co. KG Analyse d'anticorps anti-érythrocyte en présence d'un anticorps dirigé contre un antigène érythrocytaire lié en surface
IL302130A (en) 2016-12-07 2023-06-01 Molecular Templates Inc Shiga toxin a subunit effector polypeptides, shiga toxin effector scaffolds, and cell-targeting molecules for site-specific conjugation
US10799536B2 (en) 2016-12-09 2020-10-13 Onk Therapeutics Limited Method of treating multiple myeloma using natural killer cells expressing a chimeric antigen receptor for CD38
KR102590672B1 (ko) 2017-01-25 2023-10-18 몰레큘러 템플레이츠, 인코퍼레이션. 탈면역된 시가 독소 a 서브유닛 이펙터 및 cd8+ t-세포 에피토프를 포함하는 세포-표적화 분자
US20190048055A1 (en) 2017-03-31 2019-02-14 Altor Bioscience Corporation Alt-803 in combination with anti-cd38 antibody for cancer therapies
KR20250025514A (ko) 2017-06-08 2025-02-21 블랙 벨트 테라퓨틱스 리미티드 Cd38 조정 항체
CN111051344B (zh) 2017-06-08 2023-10-27 黑带医疗有限公司 Cd38调节抗体
EP3538645B1 (fr) 2017-06-20 2021-01-20 Institut Curie Cellules immunitaires défectives pour suv39h1
WO2019035938A1 (fr) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. Molécules multispécifiques se liant à bcma et leurs utilisations
AU2018316522B2 (en) 2017-08-16 2025-02-20 Black Belt Therapeutics Limited CD38 antibody
AU2018316521B2 (en) 2017-08-16 2025-01-30 Black Belt Therapeutics Limited CD38 modulating antibody
CA3075399A1 (fr) 2017-09-13 2019-03-21 Teneobio, Inc. Anticorps a chaine lourde se liant a des exoenzymes
CA3074032A1 (fr) 2017-10-02 2019-04-11 Visterra, Inc. Molecules d'anticorps se liant a cd73 et leurs utilisations
US11186649B2 (en) * 2017-10-10 2021-11-30 Sanofi Anti-CD38 antibodies and methods of use
US11618787B2 (en) 2017-10-31 2023-04-04 Janssen Biotech, Inc. Methods of treating high risk multiple myeloma
KR20200074997A (ko) 2017-11-01 2020-06-25 주노 쎄러퓨티크스 인코퍼레이티드 B-세포 성숙 항원에 특이적인 항체 및 키메릭 항원 수용체
EP3704229B1 (fr) 2017-11-01 2023-12-20 Juno Therapeutics, Inc. Procédé pour la production d'une composition de lymphocytes t
SG11202003688PA (en) 2017-11-01 2020-05-28 Juno Therapeutics Inc Process for generating therapeutic compositions of engineered cells
PL3703750T3 (pl) 2017-11-01 2025-04-07 Juno Therapeutics, Inc. Chimeryczne receptory antygenowe specyficzne dla antygenu dojrzewania komórek b i kodujące polinukleotydy
US11564946B2 (en) 2017-11-01 2023-01-31 Juno Therapeutics, Inc. Methods associated with tumor burden for assessing response to a cell therapy
US12031975B2 (en) 2017-11-01 2024-07-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
CN111542545A (zh) 2017-11-03 2020-08-14 索伦托治疗有限公司 Cd38定向嵌合抗原受体构建体
CN107936110B (zh) * 2017-11-07 2021-06-22 潍坊医学院 突变基因Nasp在狼疮性模型小鼠自身免疫病发病中的作用及机制
EP3720882A4 (fr) 2017-12-05 2021-10-27 The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center Lymphocytes t comprenant deux récepteurs antigéniques chimériques différents et leurs utilisations
CN111587254B (zh) 2017-12-05 2025-02-25 特拉维夫医疗中心医学研究基础设施及卫生服务基金 包含抗cd38和抗cd138嵌合抗原受体的t-细胞及其用途
SG11202005228YA (en) 2017-12-08 2020-07-29 Juno Therapeutics Inc Serum-free media formulation for culturing cells and methods of use thereof
CA3084446A1 (fr) 2017-12-08 2019-06-13 Juno Therapeutics, Inc. Marqueurs phenotypiques pour therapie cellulaire et procedes associes
KR102853341B1 (ko) 2017-12-08 2025-09-02 주노 쎄러퓨티크스 인코퍼레이티드 조작된 ｔ 세포의 조성물을 제조하는 방법
EP3725092A4 (fr) 2017-12-14 2021-09-22 FloDesign Sonics, Inc. Circuit d'excitation et circuit de commande de transducteur acoustique
CA3088199A1 (fr) 2018-01-12 2019-07-18 Takeda Pharmaceutical Company Limited Dosage sous-cutane d'anticorps anti-cd38
CN111886255B (zh) 2018-01-12 2025-04-04 百时美施贵宝公司 抗tim3抗体及其用途
EP3694546A1 (fr) 2018-01-30 2020-08-19 Cellectis Association comprenant des cellules immunitaires allogéniques déficientes pour un antigène présent sur les cellules t et sur des cellules pathologiques, et anticorps thérapeutique contre ledit antigène
JP6648171B2 (ja) * 2018-02-02 2020-02-14 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド 抗ｃｄ３８抗体及び弱毒化インターフェロンアルファ−２ｂとの融合物
CN110144008B (zh) * 2018-02-12 2021-03-19 杭州尚健生物技术有限公司 Cd38蛋白抗体及其应用
AU2019235626A1 (en) * 2018-03-13 2020-10-08 Pfizer Inc. Combination of CD47 blockade therapy and a CD38 antibody
EP3546475A1 (fr) 2018-03-27 2019-10-02 Sanofi Processus d'écoulement intégral pour purifier des protéines recombinées
CA3095086A1 (fr) * 2018-03-28 2019-10-03 Takeda Pharmaceutical Company Limited Administration sous-cutanee d'anticorps anti-cd38
CN108593912A (zh) * 2018-04-09 2018-09-28 北京大学深圳研究生院 一种可溶性cd38浓度的检测方法
CN110612117B (zh) 2018-04-17 2024-04-12 分子模板公司 包含去免疫化的志贺毒素a亚基支架的her2靶向分子
CA3100118A1 (fr) 2018-05-16 2019-11-21 Janssen Biotech, Inc. Anticorps bispecifiques bcma/cd3 et gprdc5d/cd3 aux fins d'utilisation dans le traitement du cancer
US11001635B2 (en) 2018-06-29 2021-05-11 Gensun Biopharma Inc. Antitumor antagonists
CA3106115A1 (fr) * 2018-07-08 2020-01-16 Specifica Inc. Banques d'anticorps ayant des caracteristiques maximisees d'aptitude au developpement d'anticorps
JP7534281B2 (ja) 2018-07-13 2024-08-14 ジェンマブ エー／エス Ｃｄ３８抗体を使用したトロゴサイトーシスを介した治療
MY205398A (en) 2018-07-13 2024-10-19 Genmab As Variants of cd38 antibody and uses thereof
KR20210059715A (ko) 2018-08-09 2021-05-25 주노 쎄러퓨티크스 인코퍼레이티드 통합된 핵산 평가 방법
CA3111651A1 (fr) 2018-09-11 2020-03-19 Jiangsu Hengrui Medicine Co., Ltd. Anticorps anti-cd38, fragment de liaison a l'antigene de celui-ci, et utilisation pharmaceutique
CN109053892B (zh) * 2018-09-19 2021-03-26 苏州思坦维生物技术股份有限公司 特异结合人及猴cd38抗原的单克隆抗体及其制备方法与应用
CN109265551B (zh) * 2018-09-25 2020-09-15 华东师范大学 Cd38抗体、嵌合抗原受体和药物
MA53920A (fr) 2018-10-17 2021-09-15 Janssen Biotech Inc Procédé de fourniture d'administration sous-cutanée d'anticorps anti-cd38
US20210388106A1 (en) 2018-10-26 2021-12-16 Teneobio, Inc. Heavy chain antibodies binding to cd38
CN113845591B (zh) * 2018-10-30 2023-10-31 迈威(上海)生物科技股份有限公司 Hsp90抗体及其在抗真菌感染中的应用
PE20211058A1 (es) 2018-11-01 2021-06-07 Juno Therapeutics Inc Receptores de antigenos quimericos especificos para el miembro d del grupo 5 de la clase c del receptor acoplado a proteina g (gprc5d)
CA3117419A1 (fr) 2018-11-01 2020-05-07 Juno Therapeutics, Inc. Methodes pour le traitement au moyen de recepteurs antigeniques chimeriques specifiques de l'antigene de maturation des lymphocytes b
SG11202104092UA (en) 2018-11-13 2021-05-28 Janssen Biotech Inc Control of trace metals during production of anti-cd38 antibodies
CN111303293B (zh) * 2018-11-14 2022-08-30 杭州尚健生物技术有限公司 一种融合蛋白及其用途
WO2020106886A1 (fr) 2018-11-20 2020-05-28 Cornell University Complexes macrocycliques de radionucléides et leur utilisation en radiothérapie du cancer
AU2019395841B2 (en) 2018-12-14 2025-02-27 Morphosys Ag Antibody formulations
US11608376B2 (en) 2018-12-21 2023-03-21 Hoffmann-La Roche Inc. Tumor-targeted agonistic CD28 antigen binding molecules
GB201900530D0 (en) * 2019-01-15 2019-03-06 Bicyclerd Ltd Bicyclic peptide ligands specific for CD38
JP7712206B2 (ja) * 2019-01-28 2025-07-23 サノフィ－アベンティス・ユー・エス・エルエルシー 多発性骨髄腫の処置方法
JP2022520572A (ja) 2019-02-12 2022-03-31 プロシーナ バイオサイエンシーズ リミテッド 免疫グロブリン軽鎖に対するモノクローナル抗体と、抗体産生細胞および他の免疫細胞上のｃｄ３８細胞膜分子に対するモノクローナル抗体の組み合わせによるａｌアミロイドーシスの処置
KR102735988B1 (ko) 2019-02-18 2024-12-03 일라이 릴리 앤드 캄파니 치료 항체 제제
JP7621263B2 (ja) * 2019-02-22 2025-01-24 武▲漢▼友芝友生物制▲薬▼股▲ふん▼有限公司 改変されたＦｃ断片、それを含む抗体、及びそれらの使用
JP2022521773A (ja) 2019-02-27 2022-04-12 ジェネンテック， インコーポレイテッド 抗ｔｉｇｉｔ抗体と抗ｃｄ２０抗体又は抗ｃｄ３８抗体とによる処置のための投薬
SG11202109645QA (en) 2019-03-05 2021-10-28 Prothena Biosciences Ltd Methods of treating al amyloidosis
SG11202107319PA (en) 2019-03-15 2021-08-30 Morphosys Ag Anti-cd38 antibodies and pharmaceutical compositions thereof for the treatment of autoantibody-mediated autoimmune disease
US20220144966A1 (en) * 2019-03-29 2022-05-12 Sorrento Therapeutics, Inc. Engineered Variant Antibodies that Bind CD38
WO2020212914A1 (fr) * 2019-04-19 2020-10-22 Janssen Biotech, Inc. Polythérapies comprenant du daratumumab, du bortézomib, du thalidomide et de la dexaméthasone et leurs utilisations
MX2021013223A (es) 2019-05-01 2022-02-17 Juno Therapeutics Inc Celulas que expresan un receptor quimerico de un locus cd247 modificado, polinucleotidos relacionados y metodos.
CN114025788A (zh) 2019-05-01 2022-02-08 朱诺治疗学股份有限公司 从经修饰的tgfbr2基因座表达重组受体的细胞、相关多核苷酸和方法
US11655302B2 (en) 2019-06-10 2023-05-23 Sanofi Anti-CD38 antibodies and formulations
JP7705353B2 (ja) 2019-06-10 2025-07-09 武田薬品工業株式会社 Ｃｄ３８抗体を使用する併用療法
MX2021016098A (es) * 2019-06-17 2022-02-03 Visterra Inc Moleculas de anticuerpos humanizados contra cd138 y usos de las mismas.
PH12021553254A1 (en) 2019-06-27 2022-09-19 Crispr Therapeutics Ag Use of chimeric antigen receptor t cells and nk cell inhibitors for treating cancer
US12319745B2 (en) 2019-07-16 2025-06-03 Inserm (Institut National De La Sante Et De La Recherche Medicale) Antibodies having specificity for CD38 and uses thereof
AU2020318781A1 (en) 2019-07-23 2022-02-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Immune cells defective for SUV39H1
US20220389103A1 (en) 2019-11-06 2022-12-08 Genentech, Inc. Diagnostic and therapeutic methods for treatment of hematologic cancers
US20210188996A1 (en) 2019-12-05 2021-06-24 Sanofi-Aventis U.S. Llc Formulations of anti-cd38 antibodies for subcutaneous administration
IL293751A (en) 2019-12-18 2022-08-01 Teneofour Inc Heavy chain antibodies binding to cd38
CA3165475A1 (fr) * 2019-12-26 2021-07-01 Ohio State Innovation Foundation Procedes et compositions d'inhibition de dihydroorotate deshydrogenease en combinaison avec un agent therapeutique anti-cd38
US11396647B2 (en) 2020-01-07 2022-07-26 Board Of Regents, The University Of Texas System Human methylthioadenosine/adenosine depleting enzyme variants for cancer therapy
JP6853392B2 (ja) * 2020-01-15 2021-03-31 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド 抗ｃｄ３８抗体及び弱毒化インターフェロンアルファ−２ｂとの融合物
KR20220130724A (ko) 2020-01-16 2022-09-27 젠맵 에이/에스 Cd38 항체의 제제 및 그의 용도
WO2021180929A1 (fr) * 2020-03-13 2021-09-16 Julius-Maximilians-Universität Würzburg Domaines de liaison à maturation d'affinité et humanisés ciblant ror2
WO2021207689A2 (fr) 2020-04-10 2021-10-14 Juno Therapeutics, Inc. Méthodes et utilisations associées à une thérapie cellulaire modifiée à l'aide d'un récepteur antigénique chimérique ciblant un antigène de maturation des lymphocytes b
KR20230024283A (ko) 2020-05-13 2023-02-20 주노 쎄러퓨티크스 인코퍼레이티드 임상 반응과 관련된 특징을 식별하는 방법 및 이의 용도
JP2023106636A (ja) * 2020-05-22 2023-08-02 国立研究開発法人医薬基盤・健康・栄養研究所 ヒト抗破傷風毒素抗体
JP2023530675A (ja) 2020-06-17 2023-07-19 ワイ－マブス セラピューティクス， インコーポレイテッド ヒト疾患の治療のためのｃｄ３８抗体
US12497463B2 (en) 2020-06-23 2025-12-16 Jiangsu Kanion Pharmaceutical Co., Ltd. Anti-CD38 antibody and use thereof
US20240216508A1 (en) 2020-06-26 2024-07-04 Juno Therapeutics Gmbh Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods
WO2021260657A1 (fr) 2020-06-26 2021-12-30 Crispr Therapeutics Ag Thérapie cellulaire allogénique de malignités de lymphocytes b à l'aide de lymphocytes t génétiquement modifiés ciblant cd19
CA3190266A1 (fr) 2020-07-30 2022-02-03 Institut Curie Cellules immunitaires defectives en socs1
CN114075283A (zh) * 2020-08-12 2022-02-22 三生国健药业（上海）股份有限公司 结合人cd38的抗体、其制备方法和用途
JP2023544407A (ja) 2020-10-05 2023-10-23 ジェネンテック， インコーポレイテッド 抗ＦｃＲＨ５／抗ＣＤ３二重特異性抗体による処置のための投与
CN114457028A (zh) * 2020-10-30 2022-05-10 未来智人再生医学研究院(广州)有限公司 一种表达cd38抗体的多能干细胞及其衍生物与应用
EP4240756A1 (fr) 2020-11-04 2023-09-13 Juno Therapeutics, Inc. Cellules exprimant un récepteur chimérique à partir d'un locus de chaîne de la superfamille des immunoglobines cd3 invariable modifié, polynucléotides et procédés associés
WO2022097047A1 (fr) * 2020-11-04 2022-05-12 Medimmune, Llc Méthodes de traitement utilisant des conjugués anticorps-médicament anti-bcma
WO2022112469A1 (fr) 2020-11-27 2022-06-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés de diagnostic et de surveillance de la nécrolyse épidermique toxique
US20220202859A1 (en) 2020-12-23 2022-06-30 Crispr Therapeutics Ag Cancer treatment using cd38 inhibitor and/or lenalidomide and t-cells expressing a chimeric antigen receptor
TW202235435A (zh) 2021-01-14 2022-09-16 德商莫菲西斯公司 抗cd38抗體及其用途
US20220275090A1 (en) 2021-02-22 2022-09-01 Janssen Biotech, Inc. Combination Therapies with Anti-CD38 Antibodies and PARP or Adenosine Receptor Inhibitors
TW202302642A (zh) 2021-03-01 2023-01-16 德商莫菲西斯公司 用於治療抗體介導移植物排斥用途之抗ｃｄ３８抗體
WO2022187406A1 (fr) 2021-03-03 2022-09-09 Juno Therapeutics, Inc. Combinaison d'une thérapie par lymphocytes t et d'un inhibiteur de dgk
CN117916256A (zh) 2021-05-06 2024-04-19 朱诺治疗学有限公司 用于刺激和转导t细胞的方法
US20240269282A1 (en) 2021-05-10 2024-08-15 Institut Curie Methods for the Treatment of Cancer, Inflammatory Diseases and Autoimmune Diseases
AR125852A1 (es) 2021-05-12 2023-08-16 Crispr Therapeutics Ag Células inmunes modificadas genéticamente que se focalizan en cd70 para su uso en tratamiento de tumores sólidos
US20220387488A1 (en) 2021-05-12 2022-12-08 Crispr Therapeutics Ag Genetically engineered immune cells targeting cd70 for use in treating hematopoietic malignancies
EP4346912A1 (fr) 2021-05-25 2024-04-10 Institut Curie Cellules myéloïdes surexprimant bcl2
WO2022271987A1 (fr) 2021-06-23 2022-12-29 TeneoFour, Inc. Anticorps anti-cd38 et leurs épitopes
TW202321303A (zh) 2021-07-19 2023-06-01 德商莫菲西斯公司 抗pla2r自體抗體媒介膜性腎病變之治療
JP2024527047A (ja) 2021-07-28 2024-07-19 ジェネンテック， インコーポレイテッド 血液がんの処置のためのｉｌ１５／ｉｌ１５ｒアルファヘテロ二量体ｆｃ融合タンパク質
TW202321308A (zh) 2021-09-30 2023-06-01 美商建南德克公司 使用抗ｔｉｇｉｔ抗體、抗ｃｄ３８抗體及ｐｄ—１軸結合拮抗劑治療血液癌症的方法
KR20240099376A (ko) 2021-11-03 2024-06-28 얀센 바이오테크 인코포레이티드 암 치료 및 bcmaxcd3 이중특이성 항체의 효능을 향상시키는 방법
KR20240099411A (ko) 2021-11-03 2024-06-28 얀센 바이오테크 인코포레이티드 항-cd38 항체를 사용한 치료에서 코르티코스테로이드 감소
CN118382456A (zh) * 2021-12-16 2024-07-23 上海宝济药业股份有限公司 抗免疫球蛋白降解酶酶切的Fc变体
EP4456910A1 (fr) 2021-12-28 2024-11-06 Mnemo Therapeutics Cellules immunitaires avec suv39h1 inactivé et tcr modifié
JP2025504002A (ja) 2022-01-28 2025-02-06 ジュノー セラピューティクス インコーポレイテッド 細胞組成物を製造する方法
JP2025508739A (ja) 2022-02-18 2025-04-10 ラクテン・メディカル，インコーポレイテッド 抗プログラム細胞死リガンド１（ｐｄ－ｌ１）抗体分子、それをコードするポリヌクレオチド、および使用方法
WO2023178323A1 (fr) * 2022-03-18 2023-09-21 Henry Ford Health System Inhibition thérapeutique de cd38 pour traiter l'hidradénite suppurée
WO2023187024A1 (fr) 2022-03-31 2023-10-05 Institut Curie Protéine rela modifiée pour induire l'expression d'interféron et cellules immunitaires modifiées ayant une expression d'interféron améliorée
WO2023191816A1 (fr) 2022-04-01 2023-10-05 Genentech, Inc. Dosage pour traitement avec des anticorps bispécifiques anti-fcrh5/anti-cd3
WO2023213969A1 (fr) 2022-05-05 2023-11-09 Juno Therapeutics Gmbh Protéine de liaison virale et réactifs, articles et méthodes d'utilisation associés
CA3251472A1 (fr) 2022-05-11 2023-11-16 Genentech, Inc. Dosage pour le traitement avec des anticorps bispécifiques anti-fcrh5/anti-cd3
US20250302954A1 (en) 2022-05-11 2025-10-02 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
WO2023230548A1 (fr) 2022-05-25 2023-11-30 Celgene Corporation Procédé de prédiction d'une réponse à une thérapie par lymphocyte t
WO2023230581A1 (fr) 2022-05-25 2023-11-30 Celgene Corporation Procédés de fabrication de thérapies par lymphocytes t
CA3258344A1 (fr) 2022-06-07 2023-12-14 Actinium Pharmaceuticals, Inc. Chélateurs et conjugués bifonctionnels
CN119585308A (zh) 2022-07-13 2025-03-07 基因泰克公司 针对用抗fcrh5/抗cd3双特异性抗体进行的治疗的给药
EP4558524A1 (fr) 2022-07-19 2025-05-28 Genentech, Inc. Dosage pour traitement avec des anticorps bispécifiques anti-fcrh5/anti-cd3
JP2025531850A (ja) 2022-09-08 2025-09-25 ジュノー セラピューティクス インコーポレイテッド Ｔ細胞療法および継続的または間欠的ｄｇｋ阻害剤投薬の組合せ
TW202423970A (zh) 2022-10-10 2024-06-16 瑞士商赫孚孟拉羅股份公司 Ｇｐｒｃ５ｄ ｔｃｂ及ｃｄ３８抗體之組合療法
CN120693520A (zh) 2022-10-14 2025-09-23 詹森药业有限公司 用于检测抗体依赖性细胞吞噬作用的方法
WO2024091991A1 (fr) 2022-10-25 2024-05-02 Genentech, Inc. Méthodes thérapeutiques et diagnostiques pour myélomes multiples
EP4612177A1 (fr) 2022-10-31 2025-09-10 Genmab A/S Anticorps cd38 et leurs utilisations
CN120282797A (zh) 2022-11-02 2025-07-08 詹森生物科技公司 治疗癌症的方法
WO2024100604A1 (fr) 2022-11-09 2024-05-16 Juno Therapeutics Gmbh Procédés de fabrication de cellules immunitaires modifiées
KR20250121074A (ko) 2022-12-09 2025-08-11 주노 쎄러퓨티크스 인코퍼레이티드 홀로그래픽 이미징을 사용하여 세포 표현형을 예측하기 위한 기계 학습 방법
CN121002052A (zh) 2023-02-03 2025-11-21 C3S2 有限公司 用于非病毒生产工程化免疫细胞的方法
AU2024270495A1 (en) 2023-05-05 2025-10-09 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2025011575A1 (fr) * 2023-07-10 2025-01-16 科济生物医药（上海）有限公司 Composition pour immunothérapie cellulaire et méthode
WO2025027003A1 (fr) * 2023-07-31 2025-02-06 Sanofi Méthodes et utilisations pour des activateurs de lymphocytes t anti-cd38 dans le traitement de lymphomes t périphériques
WO2025106474A1 (fr) 2023-11-14 2025-05-22 Genentech, Inc. Méthodes thérapeutiques et diagnostiques pour le traitement du cancer avec des anticorps bispécifiques anti-fcrh5/anti-cd3
WO2025229160A1 (fr) 2024-05-01 2025-11-06 Commit Biologics Aps Protéines modifiées activant le facteur du complément et un antigène protéique, procédés et utilisations associés
WO2025231372A2 (fr) 2024-05-03 2025-11-06 Janssen Biotech, Inc. Méthodes de traitement du myélome multiple à l'aide de cellules car-t et d'anticorps bispécifiques

Family Cites Families (331)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US941A (en) 1838-09-22 Machine for sawing shingles and staves
US6168A (en) 1849-03-13 Horizontal spark-arrester
US835A (en) 1838-07-12 X i i i x
US576A (en) 1838-01-20 Ftjbnace of stoves fob bubning anthracite
US510A (en) 1837-12-07 soeel
US6077A (en) 1849-01-30 Improved hinged claw-wrench
US5672A (en) 1848-07-18 Mark wilder
US54A (en) 1836-10-15 Art of managing and supplying fie-e for generating steam in locomotive
US5719A (en) 1848-08-22 Ditching-machine
US5922A (en) 1848-11-14 Improvement in hillside-plows
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
EP0098110B1 (fr) 1982-06-24 1989-10-18 NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD Composition à action prolongée
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4681581A (en) 1983-12-05 1987-07-21 Coates Fredrica V Adjustable size diaper and folding method therefor
CA1282721C (fr) 1984-06-04 1991-04-09 Bernard Roizman Virus de l'herpes simplex utilise comme vecteur
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (fr) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Récepteurs chimériques par liaison et expression de l'ADN
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4699880A (en) 1984-09-25 1987-10-13 Immunomedics, Inc. Method of producing monoclonal anti-idiotype antibody
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
US4824659A (en) 1985-06-07 1989-04-25 Immunomedics, Inc. Antibody conjugates
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
EP0247091B1 (fr) 1985-11-01 1993-09-29 Xoma Corporation Assemblage modulaire de genes d'anticorps, anticorps ainsi prepares et utilisation
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
US4954617A (en) 1986-07-07 1990-09-04 Trustees Of Dartmouth College Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5834185A (en) 1986-10-28 1998-11-10 Johns Hopkins University Formation of triple helix complexes of single stranded nucleic acids using nucleoside oligomers which comprise pyrimidine analogs, triple helix complexes formed thereby and oligomers used in their formation
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0307434B2 (fr) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Anticorps alteres
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
WO1988009344A1 (fr) 1987-05-21 1988-12-01 Creative Biomolecules, Inc. Proteines mutifonctionnelles a cible predeterminee
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5648471A (en) 1987-12-03 1997-07-15 Centocor, Inc. One vial method for labeling antibodies with Technetium-99m
HUT53672A (en) 1988-02-25 1990-11-28 Gen Hospital Corp Quick immunoselective cloning process
EP0404835A4 (en) 1988-03-18 1991-05-08 Us Health Novel recombinant vaccinia virus expression vectors and method of selecting same
US5716826A (en) 1988-03-21 1998-02-10 Chiron Viagene, Inc. Recombinant retroviruses
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5614404A (en) 1988-06-10 1997-03-25 Theriod Biologics, Incorporated Self-assembled, defective, non-self-propagating lentivirus particles
US5294533A (en) 1988-07-05 1994-03-15 Baylor College Of Medicine Antisense oligonucleotide antibiotics complementary to the macromolecular synthesis operon, methods of treating bacterial infections and methods for identification of bacteria
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5866701A (en) 1988-09-20 1999-02-02 The Board Of Regents For Northern Illinois University Of Dekalb HIV targeted hairpin ribozymes
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5624824A (en) 1989-03-24 1997-04-29 Yale University Targeted cleavage of RNA using eukaryotic ribonuclease P and external guide sequence
US5168053A (en) 1989-03-24 1992-12-01 Yale University Cleavage of targeted RNA by RNAase P
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
DE69032742T2 (de) 1989-08-09 1999-06-17 Rhomed, Inc., Albuquerque, N.Mex. Direkte radioetikettierung von antikörpern und sonstigen proteinen mittels technetium oder rhenium
CA2067821A1 (fr) 1989-10-24 1991-04-25 Cetus Oncology Corporation Mecanisme infectieux d'administration d'un medicament faisant appel a des vecteurs retroviraux recombinants
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
JP2507895B2 (ja) 1989-12-19 1996-06-19 工業技術院長 リボザイムの新規合成系
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
RU2128227C1 (ru) 1989-12-22 1999-03-27 Апплайд Резеч Системз АРС Холдинг Н.В. (NL) (Антильские острова) Способ активации транскрипционно-молчащего гена
US5672510A (en) 1990-01-19 1997-09-30 Genetic Therapy, Inc. Retroviral vectors
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5795721A (en) 1990-06-11 1998-08-18 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands of ICP4
US5660985A (en) 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
US5780228A (en) 1990-06-11 1998-07-14 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands to lectins
US5476766A (en) 1990-06-11 1995-12-19 Nexstar Pharmaceuticals, Inc. Ligands of thrombin
US5731424A (en) 1990-06-11 1998-03-24 Nexstar Pharmaceuticals, Inc. High affinity TGFβ nucleic acid ligands and inhibitors
US6011020A (en) 1990-06-11 2000-01-04 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US5723289A (en) 1990-06-11 1998-03-03 Nexstar Pharmaceuticals, Inc. Parallel selex
US5580737A (en) 1990-06-11 1996-12-03 Nexstar Pharmaceuticals, Inc. High-affinity nucleic acid ligands that discriminate between theophylline and caffeine
US5846713A (en) 1990-06-11 1998-12-08 Nexstar Pharmaceuticals, Inc. High affinity HKGF nucleic acid ligands and inhibitors
US6030776A (en) 1990-06-11 2000-02-29 Nexstar Pharmaceuticals, Inc. Parallel SELEX
US5503978A (en) 1990-06-11 1996-04-02 University Research Corporation Method for identification of high affinity DNA ligands of HIV-1 reverse transcriptase
US5861254A (en) 1997-01-31 1999-01-19 Nexstar Pharmaceuticals, Inc. Flow cell SELEX
US5864026A (en) 1990-06-11 1999-01-26 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue selex
US5543293A (en) 1990-06-11 1996-08-06 Nexstar Pharmaceuticals, Inc. DNA ligands of thrombin
US5869641A (en) 1990-06-11 1999-02-09 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands of CD4
US6001988A (en) 1990-06-11 1999-12-14 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands to lectins
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
US5135917A (en) 1990-07-12 1992-08-04 Nova Pharmaceutical Corporation Interleukin receptor expression inhibiting antisense oligonucleotides
IE912466A1 (en) 1990-07-13 1992-01-15 Gen Hospital Corp Rapid immunoselection cloning method
US5165424A (en) 1990-08-09 1992-11-24 Silverman Harvey N Method and system for whitening teeth
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
JP2938569B2 (ja) 1990-08-29 1999-08-23 ジェンファーム インターナショナル，インコーポレイティド 異種免疫グロブリンを作る方法及びトランスジェニックマウス
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5194594A (en) 1990-09-07 1993-03-16 Techniclone, Inc. Modified antibodies
GB9023352D0 (en) 1990-10-26 1990-12-05 Lynxvale Ltd Vaccinia vectors,vaccinia genes and expression products thereof
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5271941A (en) 1990-11-02 1993-12-21 Cho Chung Yoon S Antisense oligonucleotides of human regulatory subunit RI.sub.α of cAMP-dependent protein kinases
WO1992009690A2 (fr) 1990-12-03 1992-06-11 Genentech, Inc. Methode d'enrichissement pour des variantes de l'hormone de croissance avec des proprietes de liaison modifiees
SE9003978D0 (sv) 1990-12-13 1990-12-13 Henrik Garoff Dna expressionssystem baserade paa ett virus replikon
ATE439435T1 (de) 1991-03-01 2009-08-15 Dyax Corp Chimäres protein mit mikroprotein mit zwei oder mehr disulfidbindungen und ausgestaltungen davon
GB9105383D0 (en) 1991-03-14 1991-05-01 Immunology Ltd An immunotherapeutic for cervical cancer
US5683874A (en) 1991-03-27 1997-11-04 Research Corporation Technologies, Inc. Single-stranded circular oligonucleotides capable of forming a triplex with a target sequence
EP1471142B1 (fr) 1991-04-10 2008-11-19 The Scripps Research Institute Banques de récepteurs hétérodimères utilisant des phagémides
US6028186A (en) 1991-06-10 2000-02-22 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands of cytokines
WO1994004679A1 (fr) 1991-06-14 1994-03-03 Genentech, Inc. Procede pour fabriquer des anticorps humanises
AU2235992A (en) 1991-06-14 1993-01-12 Genpharm International, Inc. Transgenic immunodeficient non-human animals
DE4216134A1 (de) 1991-06-20 1992-12-24 Europ Lab Molekularbiolog Synthetische katalytische oligonukleotidstrukturen
WO1993000917A1 (fr) 1991-07-05 1993-01-21 Seragen, Inc. Molecules ciblees sur un recepteur du facteur de croissance epidermique, et utilisees dans le traitement de l'arthrite inflammatoire
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
DE69224906T2 (de) 1991-07-08 1998-10-29 Univ Massachusetts Thermotropes flüssig-kristallines segment-blockcopolymer
EP0605522B1 (fr) 1991-09-23 1999-06-23 Medical Research Council Méthodes de production d'anticorps humanisés
WO1993008829A1 (fr) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions induisant la destruction de cellules infectees par l'hiv
US6063630A (en) 1991-11-05 2000-05-16 Transkaryotic Therapies, Inc. Targeted introduction of DNA into primary or secondary cells and their use for gene therapy
US5968502A (en) 1991-11-05 1999-10-19 Transkaryotic Therapies, Inc. Protein production and protein delivery
CA2122365C (fr) 1991-11-26 2010-05-11 Brian Froehler Formation amelioree a triple helice et double helice avec oligomeres renfermant des pyrimidines modifiees
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5777085A (en) 1991-12-20 1998-07-07 Protein Design Labs, Inc. Humanized antibodies reactive with GPIIB/IIIA
US5652094A (en) 1992-01-31 1997-07-29 University Of Montreal Nucleozymes
WO1993016184A1 (fr) 1992-02-06 1993-08-19 Schering Corporation Fabrication, clonage et expression d'anticorps monoclonaux humanises diriges contre l'interleukine-5 humaine
DE69331089T2 (de) 1992-02-18 2002-07-18 Otsuka Kagaku K.K., Osaka Beta-Laktam und Cepham Verbindungen und Ihre Herstellung
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5693535A (en) 1992-05-14 1997-12-02 Ribozyme Pharmaceuticals, Inc. HIV targeted ribozymes
US5646020A (en) 1992-05-14 1997-07-08 Ribozyme Pharmaceuticals, Inc. Hammerhead ribozymes for preferred targets
US5610054A (en) 1992-05-14 1997-03-11 Ribozyme Pharmaceuticals, Inc. Enzymatic RNA molecule targeted against Hepatitis C virus
US5972699A (en) 1992-05-14 1999-10-26 Ribozyme Pharmaceuticals, Inc. Method and reagent for inhibiting herpes simplex virus replication
US5989906A (en) 1992-05-14 1999-11-23 Ribozyme Pharmaceuticals, Inc. Method and reagent for inhibiting P-glycoprotein (mdr-1-gene)
US6017756A (en) 1992-05-14 2000-01-25 Ribozyme Pharmaceuticals, Inc. Method and reagent for inhibiting hepatitis B virus replication
DE69332856D1 (de) 1992-07-02 2003-05-15 Sankyo Co Haarnadelförmiges ribozym
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
CA2140280A1 (fr) 1992-08-17 1994-03-03 Avi J. Ashkenazi Immunoadhesines bispecifiques
US5646042A (en) 1992-08-26 1997-07-08 Ribozyme Pharmaceuticals, Inc. C-myb targeted ribozymes
US5891684A (en) 1992-10-15 1999-04-06 Ribozyme Pharmaceuticals, Inc. Base-modified enzymatic nucleic acid
GB9223377D0 (en) 1992-11-04 1992-12-23 Medarex Inc Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
US5811300A (en) 1992-12-07 1998-09-22 Ribozyme Pharmaceuticals, Inc. TNF-α ribozymes
US5612215A (en) 1992-12-07 1997-03-18 Ribozyme Pharmaceuticals, Inc. Stromelysin targeted ribozymes
EP0682716A4 (fr) 1993-01-15 1999-10-27 New York Health Res Inst Dosages d'arn au moyen de sondes binaires d'arn et d'une ribozyme-ligase.
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US5786138A (en) 1993-01-29 1998-07-28 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Hyperstabilizing antisense nucleic acid binding agents
AU6123894A (en) 1993-01-29 1994-08-15 Board Of Trustees Of The Leland Stanford Junior University Modulation of physiological responses of lymphocytes by cd38 or antibodies thereto
ATE193301T1 (de) 1993-03-09 2000-06-15 Genzyme Corp Verfahren zur isolierung von proteinen aus milch
DE69431295T2 (de) 1993-04-21 2003-05-15 Institut Pasteur, Paris Biokompatibles implantat zur in vivo expression und sekretion von therapeutischer verbindung
CA2161351C (fr) 1993-04-26 2010-12-21 Nils Lonberg Animaux transgeniques, pouvant produire des anticorps heterologues
DE69425890D1 (de) 1993-06-04 2000-10-19 Us Health Verfahren zur behandlung von kaposi-sarcoma mit antisense-oligonukleotide
WO1994029351A2 (fr) 1993-06-16 1994-12-22 Celltech Limited Anticorps
US5962426A (en) 1993-06-25 1999-10-05 Yale University Triple-helix forming oligonucleotides for targeted mutagenesis
ATE227342T1 (de) 1993-09-02 2002-11-15 Ribozyme Pharm Inc Enzymatische nukleiksaüre die nicht-nukleotide enthaltet
CA2158937C (fr) 1993-09-15 2006-01-03 Thomas W. Dubensky, Jr. Vecteurs d'alphavirus recombinant
US5861288A (en) 1993-10-18 1999-01-19 Ribozyme Pharmaceuticals, Inc. Catalytic DNA
US5616466A (en) 1993-11-05 1997-04-01 Cantor; Glenn H. Ribozyme-mediated inhibition of bovine leukemia virus
US5578716A (en) 1993-12-01 1996-11-26 Mcgill University DNA methyltransferase antisense oligonucleotides
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5712384A (en) 1994-01-05 1998-01-27 Gene Shears Pty Ltd. Ribozymes targeting retroviral packaging sequence expression constructs and recombinant retroviruses containing such constructs
US5641754A (en) 1994-01-10 1997-06-24 The Board Of Regents Of The University Of Nebraska Antisense oligonucleotide compositions for selectively killing cancer cells
US5580766A (en) 1994-01-14 1996-12-03 Alexion Pharmaceuticals, Inc. Retroviral vector particles for transducing non-proliferating cells
US5631359A (en) 1994-10-11 1997-05-20 Ribozyme Pharmaceuticals, Inc. Hairpin ribozymes
US5639647A (en) 1994-03-29 1997-06-17 Ribozyme Pharmaceuticals, Inc. 2'-deoxy-2'alkylnucleotide containing nucleic acid
US5869248A (en) 1994-03-07 1999-02-09 Yale University Targeted cleavage of RNA using ribonuclease P targeting and cleavage sequences
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
US5879687A (en) 1994-04-22 1999-03-09 Corixa Corporation Methods for enhancement of protective immune responses
US5580967A (en) 1994-05-13 1996-12-03 The Scripps Research Institute Optimized catalytic DNA-cleaving ribozymes
US5683902A (en) 1994-05-13 1997-11-04 Northern Illinois University Human papilloma virus inhibition by a hairpin ribozyme
US5595873A (en) 1994-05-13 1997-01-21 The Scripps Research Institute T. thermophila group I introns that cleave amide bonds
US5658785A (en) 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods
US5650316A (en) 1994-06-06 1997-07-22 Research Development Foundation Uses of triplex forming oligonucleotides for the treatment of human diseases
US5998193A (en) 1994-06-24 1999-12-07 Gene Shears Pty., Ltd. Ribozymes with optimized hybridizing arms, stems, and loops, tRNA embedded ribozymes and compositions thereof
US5633133A (en) 1994-07-14 1997-05-27 Long; David M. Ligation with hammerhead ribozymes
AU3222795A (en) 1994-08-09 1996-03-07 Ciba-Geigy Ag Antitumor antisense oligonucleotides
US5688670A (en) 1994-09-01 1997-11-18 The General Hospital Corporation Self-modifying RNA molecules and methods of making
US5989908A (en) 1994-09-12 1999-11-23 City Of Hope Modulation of drug and radiation resistant genes
US5599706A (en) 1994-09-23 1997-02-04 Stinchcomb; Dan T. Ribozymes targeted to apo(a) mRNA
US5856103A (en) 1994-10-07 1999-01-05 Board Of Regents The University Of Texas Method for selectively ranking sequences for antisense targeting
JPH08113591A (ja) 1994-10-14 1996-05-07 Taiho Yakuhin Kogyo Kk オリゴヌクレオチド及びこれを有効成分とする制癌剤
US20020164788A1 (en) 1994-12-02 2002-11-07 The Wellcome Foundation Limited Humanized antibodies to CD38
GB9424449D0 (en) * 1994-12-02 1995-01-18 Wellcome Found Antibodies
US5807718A (en) 1994-12-02 1998-09-15 The Scripps Research Institute Enzymatic DNA molecules
US5683873A (en) 1995-01-13 1997-11-04 Innovir Laboratories, Inc. EGS-mediated inactivation of target RNA
US5631146A (en) 1995-01-19 1997-05-20 The General Hospital Corporation DNA aptamers and catalysts that bind adenosine or adenosine-5'-phosphates and methods for isolation thereof
US5994320A (en) 1995-02-06 1999-11-30 Regents Of The University Of Minnesota Antisense oligonucleotides and methods for treating central nervous system tumors
IT1275862B1 (it) 1995-03-03 1997-10-24 Consiglio Nazionale Ricerche Trascritto antisenso associato ad alcuni tipi di cellule tumorali ed oligodeossinucleotidi sintetici utili nella diagnosi e nel trattamento
US5770715A (en) 1995-03-22 1998-06-23 Toagosei Co., Ltd. Hammerhead-like nucleic acid analogues and their synthesis
US5703057A (en) 1995-04-07 1997-12-30 Board Of Regents The University Of Texas System Expression library immunization
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
WO1996033279A2 (fr) 1995-04-21 1996-10-24 Abbott Laboratories Procede de clonage de repertoires, produits derives de ce dernier et utilisations desdits produits
US6013443A (en) 1995-05-03 2000-01-11 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue SELEX
US5646031A (en) 1995-05-16 1997-07-08 Northern Illinois University SArMV and sCYMVI hairpin ribozymes
US5910408A (en) 1995-06-07 1999-06-08 The General Hospital Corporation Catalytic DNA having ligase activity
AU726844B2 (en) 1995-06-07 2000-11-23 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands that bind to and inhibit DNA polymerases
US6040296A (en) 1995-06-07 2000-03-21 East Carolina University Specific antisense oligonucleotide composition & method for treatment of disorders associated with bronchoconstriction and lung inflammation
US5693773A (en) 1995-06-07 1997-12-02 Hybridon Incorporated Triplex-forming antisense oligonucleotides having abasic linkers targeting nucleic acids comprising mixed sequences of purines and pyrimidines
US5877021A (en) 1995-07-07 1999-03-02 Ribozyme Pharmaceuticals, Inc. B7-1 targeted ribozymes
WO1997004748A2 (fr) 1995-08-01 1997-02-13 Advanced Therapies, Inc. Enveloppes virales artificielles renforcees pour l'apport de substances therapeutiques dans les cellules
NO953680D0 (no) 1995-09-18 1995-09-18 Hans Prydz Cellesyklusenzymer
AU7286696A (en) 1995-10-13 1997-05-07 F. Hoffmann-La Roche Ag Antisense oligomers
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
AU7572096A (en) 1995-11-14 1997-06-05 Vimrx Holdings, Ltd. Chimeric oligomers having an rna-cleavage activity
CN1202900A (zh) 1995-11-21 1998-12-23 Icn药品公司 用il－8和il－8受体的反义寡核苷酸抑制肿瘤生长
US5998203A (en) 1996-04-16 1999-12-07 Ribozyme Pharmaceuticals, Inc. Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
JP2000506384A (ja) 1996-02-15 2000-05-30 ナショナル インスティチューツ オブ ヘルス ＲＮａｓｅ Ｌ アクチベーター及びＲＳＶ感染の治療に有効なアンチセンスオリゴヌクレオチド
US5877162A (en) 1996-03-14 1999-03-02 Innovir Laboratories, Inc. Short external guide sequences
DE69737867T2 (de) 1996-05-03 2007-10-18 Immunomedics, Inc. Zielgerichtete kombinations-immuntherapie für krebs
US6261552B1 (en) 1997-05-22 2001-07-17 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus vectors
US5792613A (en) 1996-06-12 1998-08-11 The Curators Of The University Of Missouri Method for obtaining RNA aptamers based on shape selection
US5955590A (en) 1996-07-15 1999-09-21 Worcester Foundation For Biomedical Research Conjugates of minor groove DNA binders with antisense oligonucleotides
US6869793B2 (en) 1996-09-24 2005-03-22 Bavarian Nordic Research Institute Recombinant MVA virus expressing dengue virus antigens, and the use thereof in vaccines
JP4233608B2 (ja) 1996-10-15 2009-03-04 塩野義製薬株式会社 自己抗体測定方法
DE69719529T2 (de) 1996-10-17 2003-12-11 Immunomedics, Inc. Nichtantigenes toxinkonjugat und fusionsprotein eines internalisierendes rezeptorsystems
US6051698A (en) 1997-06-06 2000-04-18 Janjic; Nebojsa Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
US5874566A (en) 1996-10-25 1999-02-23 Hisamitsu Pharmaceutical Co. Inc. Il-15 triplex oligonucleotides
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
WO1998022588A2 (fr) 1996-11-20 1998-05-28 Introgen Therapeutics, Inc. Procede ameliore pour production et purification de vecteurs d'adenovirus
WO2000006194A2 (fr) 1997-02-05 2000-02-10 Biotransplant, Inc. Depletion de cellules responsables du rejet d'une greffe induit par des anticorps
US6046004A (en) 1997-02-27 2000-04-04 Lorne Park Research, Inc. Solution hybridization of nucleic acids with antisense probes having modified backbones
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
ES2248898T3 (es) 1997-05-02 2006-03-16 The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services Inmunotoxinas que comprenden una proteina onc dirigida contra celulas malignas.
GB2339430A (en) 1997-05-21 2000-01-26 Biovation Ltd Method for the production of non-immunogenic proteins
DE69820450T2 (de) 1997-06-09 2004-05-27 Genvec, Inc. Chimäre vektoren, die die verpackungsregion eines phagengenoms und einen teil des genoms eines eukaryontischen virus enthalten
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6300483B1 (en) 1997-06-19 2001-10-09 Ribozyme Pharmaceuticals, Inc. Compositions inducing cleavage of RNA motifs
CA2295207A1 (fr) 1997-06-19 1998-12-23 Innovir Laboratories, Inc. Ribozymes en tete de marteau a fonction de clivage etendue
JPH1142091A (ja) 1997-07-25 1999-02-16 Toagosei Co Ltd アンチセンス核酸化合物
CA2304173A1 (fr) 1997-09-23 1999-04-01 Genvec, Inc. Plasmides pour la construction de vecteurs viraux eucaryotes
US6046319A (en) 1997-10-22 2000-04-04 University Technologies International, Inc. Antisense oligodeoxynucleotides regulating expression of TNF-α
US6399383B1 (en) 1997-10-28 2002-06-04 Maxygen, Inc. Human papilloma virus vectors
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US6719977B1 (en) 1998-02-12 2004-04-13 The General Hospital Corporation Methods to potentiate cancer therapies
US5922576A (en) 1998-02-27 1999-07-13 The John Hopkins University Simplified system for generating recombinant adenoviruses
WO1999050392A1 (fr) 1998-03-31 1999-10-07 Geron Corporation Techniques et compositions permettant de faire apparaitre une reponse immunitaire a un antigene de telomerase
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
PT1071700E (pt) 1998-04-20 2010-04-23 Glycart Biotechnology Ag Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
PL343630A1 (en) 1998-04-22 2001-08-27 Genvec Inc Efficient purification of adenovirus
CA2329940A1 (fr) * 1998-06-05 1999-12-09 Mayo Foundation For Medical Education And Research Traitement du myelome multiple au moyen d'anticorps du cd38 obtenus par genie genetique
US6007995A (en) 1998-06-26 1999-12-28 Isis Pharmaceuticals Inc. Antisense inhibition of TNFR1 expression
DE69939939D1 (de) 1998-08-11 2009-01-02 Idec Pharma Corp Kombinationstherapien gegen b-zell-lymphome beinhaltend die verabreichung von anti-cd20-antikörpern
US5965358A (en) 1998-08-26 1999-10-12 Genvec, Inc. Method for assessing the relative purity of viral gene transfer vector stocks
US6875741B2 (en) 1998-09-02 2005-04-05 Renuka Pillutla Insulin and IGF-1 receptor agonists and antagonists
WO2000014244A2 (fr) 1998-09-04 2000-03-16 Connaught Laboratories Limited Traitement du cancer du col utérin
US6387888B1 (en) 1998-09-30 2002-05-14 American Foundation For Biological Research, Inc. Immunotherapy of cancer through expression of truncated tumor or tumor-associated antigen
WO2000039318A1 (fr) 1998-12-31 2000-07-06 Chiron Corporation Compositions et methodes permettant l'encapsidation de vecteurs d'alphavirus
US7223397B1 (en) 1999-01-07 2007-05-29 Research Development Foundation Potentiation of anti-CD38-Immunotoxin cytotoxicity
ES2694002T3 (es) 1999-01-15 2018-12-17 Genentech, Inc. Polipéptido que comprende una región Fc de IgG1 humana variante
DE60013773T2 (de) 1999-02-03 2005-11-10 Biosante Pharmaceuticals, Inc. Methoden zur Herstellung von therapeutischen Kalziumphosphat Partikeln
US6013522A (en) 1999-02-23 2000-01-11 Isis Pharmaceuticals Inc. Antisense inhibition of human Smad1 expression
WO2000061739A1 (fr) 1999-04-09 2000-10-19 Kyowa Hakko Kogyo Co., Ltd. Methode de regulation de l'activite d'une molecule immunologiquement fonctionnelle
US20050037969A1 (en) * 1999-05-14 2005-02-17 Arbor Vita Corporation Molecular interactions in hematopoietic cells
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
US6025198A (en) 1999-06-25 2000-02-15 Isis Pharmaceuticals Inc. Antisense modulation of Ship-2 expression
US6033910A (en) 1999-07-19 2000-03-07 Isis Pharmaceuticals Inc. Antisense inhibition of MAP kinase kinase 6 expression
ATE384744T1 (de) 1999-07-29 2008-02-15 Medarex Inc Menschliche antikörper gegen her2/neu
EP1212422B1 (fr) 1999-08-24 2007-02-21 Medarex, Inc. Anticorps contre l'antigene ctla-4 humain et utilisation
AU2001245793A1 (en) 2000-03-16 2001-09-24 Cold Spring Harbor Laboratory Methods and compositions for rna interference
AU2001249380A1 (en) 2000-03-22 2001-11-07 Chiron Corporation Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
EP1309726B2 (fr) 2000-03-30 2018-10-03 Whitehead Institute For Biomedical Research Mediateurs d'interference arn specifiques de sequences arn
US6168941B1 (en) 2000-04-07 2001-01-02 Genvec, Inc. Method of producing adenoviral vector stocks
CA2407050A1 (fr) 2000-04-25 2001-11-01 Chiron Corporation Vecteurs a base d'alphavirus destines a l'infection durable
EP1174440A1 (fr) 2000-07-19 2002-01-23 U-BISys B.V. Un épitope exprimé sélectivement sur la molécule humaine CD38 et détecté par un fragment d'un anticorps humain de forme scFv dérivé d'une librairie "phage display"
EP1326998A4 (fr) 2000-10-17 2005-05-11 Trudeau Inst Inc Chimiotaxie modulee du gene cd38
US20070042436A1 (en) 2000-10-17 2007-02-22 Lund Frances E CD38 modulated chemotaxis
CN1205479C (zh) * 2000-10-31 2005-06-08 杨梦甦 免疫学诊断蛋白芯片制备方法
US20020132788A1 (en) 2000-11-06 2002-09-19 David Lewis Inhibition of gene expression by delivery of small interfering RNA to post-embryonic animal cells in vivo
US6713055B2 (en) 2000-11-27 2004-03-30 Geron Corporation Glycosyltransferase vectors for treating cancer
KR100857943B1 (ko) 2000-11-30 2008-09-09 메다렉스, 인코포레이티드 인간 항체의 제조를 위한 형질전환 트랜스염색체 설치류
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
RU2335507C2 (ru) 2001-06-13 2008-10-10 Генмаб А/С Человеческие моноклональные антитела к рецептору эпидермального фактора роста (egfr), способ их получения и их использование, гибридома, трансфектома, трансгенное животное, экспрессионный вектор
US20040166490A1 (en) * 2002-12-17 2004-08-26 Morris David W. Novel therapeutic targets in cancer
US20040063654A1 (en) 2001-11-02 2004-04-01 Davis Mark E. Methods and compositions for therapeutic use of RNA interference
WO2004033620A2 (fr) 2001-11-02 2004-04-22 Insert Therapeutics, Inc. Procedes et compositions permettant l'utilisation therapeutique de l'interference arn
AR039067A1 (es) * 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
AU2002360394A1 (en) 2001-11-16 2003-06-10 University Of Massachusetts Facilitation of rna interference
US20030167490A1 (en) 2001-11-26 2003-09-04 Hunter Craig P. Gene silencing by systemic RNA interference
AU2002359464A1 (en) 2001-11-30 2003-06-17 Genvec, Inc. Angiopioetin related factors
US20040009498A1 (en) 2002-01-14 2004-01-15 Diversa Corporation Chimeric antigen binding molecules and methods for making and using them
WO2003080672A1 (fr) 2002-03-22 2003-10-02 Aprogen, Inc. Anticorps humanise et procede de preparation correspondant
US20040019915A1 (en) 2002-04-01 2004-01-29 Challita-Eid Pia M. Nucleic acid and corresponding protein entitled 213P1F11 useful in treatment and detection of cancer
WO2004016735A2 (fr) 2002-05-23 2004-02-26 Ceptyr, Inc. Modulation de la transduction du signal biologique par interference arn
CA2486658C (fr) 2002-05-31 2014-07-29 The Regents Of The University Of California Procede d'interference efficace par arn dans des cellules de mammifere
EP1532271A4 (fr) 2002-06-12 2006-10-18 Ambion Inc Methodes et compositions relatives a des polypeptides a domaines rnase iii mediant des interferences par l'arn
EP1393720A1 (fr) 2002-08-27 2004-03-03 Universiteit Utrecht Vesicules encapsulant des corticosteroides pour le traitement du cancer
PT1558648E (pt) * 2002-10-17 2012-04-23 Genmab As Anticorpos monoclonais humanos contra cd20
NZ540555A (en) * 2002-11-15 2008-04-30 Genmab As Antibody therapeutics for treatingand/or preventing diseases associated with cells expressing CD25, including autoimmune diseases, inflammatory and hyperproliferative skin disorders
MXPA05010778A (es) * 2003-04-09 2005-12-12 Genentech Inc Terapia para enfermedad autoinmune en un paciente con una respuesta inadecuada a un inhibidor tnf-alfa.
EP2216342B1 (fr) 2003-07-31 2015-04-22 Immunomedics, Inc. Anticorps anti-CD19
US20070031406A1 (en) 2003-10-22 2007-02-08 Zand Martin S Anti-thymocyte antiserum and use thereof to trigger b cell apoptosis
JP4765040B2 (ja) 2003-11-04 2011-09-07 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 多発性骨髄腫の処置のためのアンタゴニスト抗ｃｄ４０モノクローナル抗体の使用
MXPA06008700A (es) 2004-02-06 2007-01-19 Morphosys Ag Anticuerpos anti-cd38 humanos y usos para los mismos.
WO2006125640A2 (fr) 2005-05-24 2006-11-30 Morphosys Ag Production et profilage d'anticorps therapeutiques entierement humains hucal gold®; propres a la molecule cd38 humaine
JP2008504013A (ja) 2004-02-06 2008-02-14 モルフォシス・アクチェンゲゼルシャフト 抗ｃｄ３８ヒト抗体及びその用途
US20050266008A1 (en) * 2004-03-29 2005-12-01 Medarex, Inc. Human anti-IRTA-5 antibodies
US20060019303A1 (en) * 2004-07-23 2006-01-26 Boehringer Ingelheim Pharmaceuticals, Inc. Method to identify and analyze genes having modified expression in stimulated T cells
EA037929B1 (ru) 2005-03-23 2021-06-08 Генмаб А/С Антитела к cd38 человека и их применение
ME03503B (fr) * 2006-09-26 2020-04-20 Genmab As Traitement combiné de tumeurs exprimant la cd38
US20090076249A1 (en) 2007-09-19 2009-03-19 Michel De Weers Antibodies against CD38 for treatment of multiple myeloma
SG11201701867SA (en) * 2014-09-09 2017-04-27 Janssen Biotech Inc Combination therapies with anti-cd38 antibodies
WO2016089960A1 (fr) * 2014-12-04 2016-06-09 Janssen Biotech, Inc. Anticorps anti-cd38 pour le traitement de la leucémie aiguë myéloïde
US10668149B2 (en) * 2015-06-22 2020-06-02 Janssen Biotech, Inc. Combination therapies for heme malignancies with anti-CD38 antibodies and survivin inhibitors
EP3313441B1 (fr) * 2015-06-24 2024-02-21 Janssen Biotech, Inc. Modulation immunitaire et traitement de tumeurs solides avec des anticorps se liant spécifiquement à cd38

Also Published As

Publication number Publication date
AU2006226733B8 (en) 2013-01-10
BRPI0608927B1 (pt) 2021-11-23
LTPA2017040I1 (lt) 2018-01-10
RS59399B1 (sr) 2019-11-29
US20200283542A1 (en) 2020-09-10
NL300915I2 (nl) 2020-10-26
AU2006226733A8 (en) 2013-01-10
SG10201912554TA (en) 2020-02-27
IL304150A (en) 2023-09-01
CA2602375A1 (fr) 2006-09-28
ME03528B (fr) 2020-04-20
EP2535355A3 (fr) 2013-02-20
AU2006226733C1 (en) 2019-02-14
JP2020028294A (ja) 2020-02-27
EP3153525A1 (fr) 2017-04-12
MX2007011064A (es) 2008-02-19
JP2019146560A (ja) 2019-09-05
EP2551282A3 (fr) 2013-02-13
JP5225069B2 (ja) 2013-07-03
CY1119454T1 (el) 2018-03-07
IL185751A0 (en) 2008-01-06
HRP20191768T1 (hr) 2019-12-27
JP5971918B2 (ja) 2016-08-17
US20110099647A1 (en) 2011-04-28
CN101218256B (zh) 2017-04-19
AU2006226733C9 (en) 2019-03-14
CY1118369T1 (el) 2017-06-28
EP3312196B1 (fr) 2019-07-17
DK2567976T3 (en) 2017-10-23
US7829673B2 (en) 2010-11-09
NL300915I1 (fr) 2017-12-06
JP6952088B2 (ja) 2021-10-20
JP2008533977A (ja) 2008-08-28
JP6494053B2 (ja) 2019-04-03
WO2006099875A8 (fr) 2007-05-03
EP2535355A2 (fr) 2012-12-19
AU2006226733A1 (en) 2006-09-28
IL272273A (en) 2020-02-27
US20240132620A1 (en) 2024-04-25
EA201100694A1 (ru) 2012-02-28
KR20070116137A (ko) 2007-12-06
IL231919B (en) 2020-02-27
CN112480257A (zh) 2021-03-12
IL231919A0 (en) 2014-05-28
HK1107826A1 (zh) 2008-04-18
JP6777779B2 (ja) 2020-10-28
IL284991A (en) 2021-08-31
CN107033243A (zh) 2017-08-11
JP2021121195A (ja) 2021-08-26
NZ561883A (en) 2010-11-26
CY2017044I2 (el) 2018-09-05
EP2535355B1 (fr) 2019-01-02
IL296666A (en) 2022-11-01
EA015584B1 (ru) 2011-10-31
EP1866338A1 (fr) 2007-12-19
CN119119271A (zh) 2024-12-13
SI2567976T1 (sl) 2017-11-30
LUC00053I1 (fr) 2017-12-07
EA037929B1 (ru) 2021-06-08
US9187565B2 (en) 2015-11-17
EA200702053A1 (ru) 2008-02-28
ES2716874T3 (es) 2019-06-17
IL185751A (en) 2014-04-30
JP2016169226A (ja) 2016-09-23
FR18C1003I2 (fr) 2020-02-28
BRPI0608927A2 (pt) 2010-11-09
CA2602375C (fr) 2018-07-24
CN101218256A (zh) 2008-07-09
JP2024059959A (ja) 2024-05-01
EP3312196A1 (fr) 2018-04-25
EP2567976B1 (fr) 2017-07-19
LUC00053I9 (fr) 2018-07-03
JP2020141689A (ja) 2020-09-10
US20240228662A9 (en) 2024-07-11
EP1866338B1 (fr) 2016-09-21
JP2023017781A (ja) 2023-02-07
US20090148449A1 (en) 2009-06-11
PL2567976T3 (pl) 2018-01-31
JP2012070737A (ja) 2012-04-12
JP2018080171A (ja) 2018-05-24
IL316252A (en) 2024-12-01
ZA200709003B (en) 2009-05-27
HRP20161766T1 (hr) 2017-02-24
IL322052A (en) 2025-09-01
EP2567976A3 (fr) 2013-04-03
EP2551282A2 (fr) 2013-01-30
EP2567976A2 (fr) 2013-03-13
LTC2567976I2 (lt) 2019-06-25
JP2019037228A (ja) 2019-03-14
NZ586780A (en) 2012-02-24
CN107033243B (zh) 2020-12-15
US20160130362A1 (en) 2016-05-12
AU2006226733B2 (en) 2012-12-06
JP6578423B2 (ja) 2019-09-18
JP2014110800A (ja) 2014-06-19
WO2006099875A1 (fr) 2006-09-28
CY2017044I1 (el) 2018-09-05
KR101433381B1 (ko) 2014-10-02

Similar Documents

Publication Publication Date Title
LUC00053I9 (fr) Anticorps diriges contre cd38 pour le traitement du myelome multiple
WO2005103081A3 (fr) Anticorps monoclonaux humains diriges contre cd20
WO2009083009A3 (fr) Anticorps monoclonaux anti-cd32b
EA201100923A1 (ru) Антитела человека против тканевого фактора
TN2010000210A1 (en) Monoclonal antibodies that bind to hgm-csf and medical compositions comprising same
WO2009061996A3 (fr) Anticorps qui se lient à la cellule dendritique et épithéliale 205 (dec-205) humaine
EP2582722A4 (fr) Anticorps contre gd2
UA92505C2 (ru) Композиции на основе антитела против cd3
JOP20210044A1 (ar) الأجسام المضادة لـ cd38
ME03608B (fr) Anticorps monoclonaux contre la claudine-18 pour le traitement contre le cancer
UA107490C2 (uk) TNF-α-ЗВ'ЯЗУВАЛЬНИЙ БІЛОК
WO2011130434A3 (fr) Anticorps qui se lient au cd27 humain et utilisations de ceux-ci
EA200801842A1 (ru) Антитела против бета-амилоидного пептида
WO2008112003A3 (fr) Agents liants cibles diriges contre pdgfr-alpha et utilisations associees
WO2008027739A3 (fr) Anticorps vis-à-vis de ntb-a
EA201290849A1 (ru) Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора (tfpi)
WO2004094473A3 (fr) Anticorps humanises du recepteur 1 alpha d'interferon (ifnar-1)
EA200702634A1 (ru) Гуманизированные антитела, специфичные в отношении nogo-a, и их фармацевтические применения
WO2007007159A3 (fr) Anticorps anti-madcam servant a traiter des troubles uterins
WO2007007160A3 (fr) Anticorps anti-madcam servant a traiter la fievre
EA202190387A1 (ru) Антитело к cd38 человека и его применение
UA102085C2 (ru) ВЫДЕЛЕННОЕ МОНОКЛОНАЛЬНОЕ АНТИТЕЛО, КОТОРОЕ СВЯЗЫВАЕТСЯ С hGM-CSF, И КОМПОЗИЦИЯ МЕДИЦИНСКОГО НАЗНАЧЕНИЯ, КОТОРАЯ ЕГО СОДЕРЖИТ
SG10201909377XA (en) Antibodies that bind human cd27 and uses thereof
HK1187928A1 (zh) 识别磷酸化-tau的抗体